LIfT BioSciences

Alex Blyth, Chief Executive Officer of LIfT BioSciences commented: “On behalf of LIfT’s Board of Directors, I am pleased to welcome Tony to the Company as Chairman. Tony has extremely relevant experience, having played a key role in successfully bringing three new drug modalities to the market, extensive experience in immuno-oncology, and has helped build several multi-billion-dollar companies from start-up stage. This wealth of experience will prove invaluable to LIfT as we prepare to move into clinical trials for our allogeneic first-in-class neutrophil-based immuno-cell therapy and other exciting pipeline developments.”